文献速递前列腺癌

前列腺导管内癌的预后影响:系统评价与荟萃分析

The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2020-07-23

该系统评价与荟萃分析纳入32项研究共179,766例患者,评估前列腺导管内癌对前列腺癌患者预后的影响。在局限性前列腺癌中,导管内病变与更低的生化复发无生存(合并HR 2.09,95%CI 1.75-2.50)和癌症特异性生存(合并HR 2.93,95%CI 2.25-3.81)相关;在晚期前列腺癌中,导管内病变与更低的总生存(合并HR 1.75,95%CI 1.43-2.14)相关。

要点

  • 导管内癌是前列腺癌侵袭性的组织病理学特征,与更差肿瘤学结局相关。
  • 局限性和晚期前列腺癌中,导管内病变均预示不良生存。
  • 病理医生应评估并报告所有前列腺标本中导管内病变的存在。

核心结论

  • 导管内病变是生物学和临床上侵袭性前列腺癌的组织病理学特征,在局限性和晚期前列腺癌中均导致更差的肿瘤学结局,无论评估活检还是前列腺切除标本。

主要发现

  • 在局限性前列腺癌中,导管内病变与更低的生化复发无生存(合并HR 2.09,95%CI 1.75-2.50)和癌症特异性生存(合并HR 2.93,95%CI 2.25-3.81)相关。
  • 在晚期前列腺癌中,有导管内病变患者的总生存低于无导管内病变患者(合并HR 1.75,95%CI 1.43-2.14)。
  • 按标本类型亚组分析显示,导管内癌在活检和前列腺切除标本中均为显著负面预后因素。
  • 基于导管内癌组织病理学定义的亚组分析表明,几乎在所有定义下,导管内病变均与更低的生化复发无生存、癌症特异性生存和总生存显著相关。

临床怎么用

  • 病理医生应评估并报告所有前列腺标本中导管内病变的存在。
  • 泌尿外科医生和放疗科医生应在临床决策中考虑导管内病变这一不良特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This systematic review and meta-analysis aimed to assess the prognostic impact of intraductal carcinoma of the prostate in patients with prostate cancer. MATERIALS AND METHODS: A systematic search was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement. We searched PubMed®, Web of Science™, the Cochrane Library and Scopus® up to October 2019. The end points were biochemical recurrence-free, cancer specific and overall survival. RESULTS: We identified 32 studies with 179,766 patients. A total of 31 studies containing 179,721 patients with localized and advanced prostate cancer were eligible for meta-analysis. In localized prostate cancer intraductal disease was associated with adverse outcomes including lower biochemical recurrence-free survival (pooled HR 2.09, 95% CI 1.75-2.50) and cancer specific survival (pooled HR 2.93, 95% CI 2.25-3.81). In advanced prostate cancer overall survival was lower in patients with vs without intraductal disease (pooled HR 1.75, 95% CI 1.43-2.14). Subgroup analysis by specimen type revealed that intraductal carcinoma of the prostate is a significant negative prognostic factor in both biopsies and prostatectomy specimens. Moreover, subgroup analyses based on the histopathological definitions of intraductal carcinoma of the prostate indicated that intraductal disease was significantly associated with lower biochemical recurrence-free, cancer specific and overall survival for almost all definitions. CONCLUSIONS: Intraductal disease is a histopathological feature of biologically and clinically aggressive prostate cancer. It confers worse oncologic outcomes in both localized and advanced prostate cancer, whether assessed in biopsy or prostatectomy specimen. The pathologist should assess for and report on the presence of intraductal disease in all prostate specimens. The urologist and radiation oncologist should consider this adverse feature in their clinical decision making.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Miura N, Mori K, Mostafaei H, et al. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. J Urol. 2020. PMID: 32698712. doi:10.1097/JU.0000000000001290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。